<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25006">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01841814</url>
  </required_header>
  <id_info>
    <org_study_id>PI11-Dr.DAMAJ/PACCOU</org_study_id>
    <nct_id>NCT01841814</nct_id>
  </id_info>
  <brief_title>Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy</brief_title>
  <acronym>LYMPHOS</acronym>
  <official_title>Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy: Prospective Longitudinal Study Over 12 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <authority>FRANCE: National Security Agency of Medicines and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months
      during the therapeutic management of patients with lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Measurement of bone mineral density (BMD).</measure>
    <time_frame>Change from Baseline of bone mineral density at 12 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will have a review of bone densitometry.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma.</condition>
  <condition>Osteoporosis.</condition>
  <arm_group>
    <arm_group_label>lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Bone densitometry.</intervention_name>
    <arm_group_label>lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 to 80 with lymphoma,

          -  Histological diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) of
             follicular or aggressive (large cell or other),

          -  Patients who have not yet started their chemotherapy or who have started for less
             than a month

          -  Patient has signed informed consent.

        Exclusion Criteria:

          -  Pathological fractures at the time of initial diagnosis of lymphoma,

          -  Compression of neurological epidural,

          -  Patients receiving treatment for osteoporosis (including bisphosphonates, selective
             modulators of estrogen receptor, calcitonin and parathyroid hormone Teriparatide).

          -  Discovery of osteoporosis or osteopenia fracture during the initial evaluation
             requiring the establishment of an osteoporosis treatment,

          -  Radiotherapy to the lumbar spine or hip studied,

          -  Location of bone lymphoma in the lumbar spine or hip studied,

          -  History of disorders affecting bone metabolism (prostate cancer with androgen,
             stomach cancer, hyperparathyroidism, hyperthyroidism, uncontrolled ...)

          -  A person incapable of giving consent personally,

          -  Pregnant or breastfeeding women,

          -  Protected Person (under guardianship)

          -  Patient not affiliated with a social security system.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gandhi DAMAJ, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU d'Amiens France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gandhi DAMAJ</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 24, 2013</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Patient with</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
